Jessica Emerson

Jessica Emerson supports the National Institute of Allergy and Infectious Diseases (NIAID) in executing critical procurement strategies aligned with the agency’s mission to advance biomedical countermeasures against infectious, immunologic, and allergic diseases. She manages acquisitions for high-containment laboratory infrastructure, analytical instrumentation, and biological product manufacturing services essential to public health preparedness. Her work directly enables NIAID’s research and response capabilities by securing specialized scientific equipment and biosafety-compliant manufacturing solutions. She typically handles complex, technical contracts requiring stringent regulatory adherence and rapid deployment timelines to address emerging threats. Emerson maintains longstanding procurement relationships with Quality Biological, Inc. and GENOMIC LABS LTD, both of which provide essential biological reagents, viral vectors, and high-containment manufacturing services. Her contracting approach emphasizes vendor reliability, compliance with biosafety level (BSL-3/4) standards, and consistent supply chain integrity for mission-critical research inputs. These partnerships are characterized by long-term, performance-based agreements rather than transactional purchases, reflecting a strategic focus on continuity and scientific rigor in supporting NIAID’s laboratory and clinical development pipelines. Emerson’s contracting portfolio is entirely non-set-aside, with 100% of awards issued under full and open competition. This reflects a deliberate emphasis on technical capability and scalability over socioeconomic preferences, prioritizing the highest-quality providers capable of meeting stringent biosafety and regulatory requirements. While small business participation is not formally incentivized through set-asides, her awards remain open to all qualified vendors, ensuring competitive rigor and technical excellence. Her primary procurement focus lies in NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 334516 (Biological Product Manufacturing), encompassing next-generation sequencing platforms, biosafety cabinets, viral vector production systems, and GMP-compliant biological reagents. Her domain expertise centers on high-containment research infrastructure, diagnostic development tools, and specialized manufacturing processes critical to vaccine and therapeutic pipeline advancement.